Literature DB >> 32061625

Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.

Milton Packer1.   

Abstract

Entities:  

Year:  2020        PMID： 32061625     DOI： 10.1016/j.amjmed.2020.01.016

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  3 in total

1.  Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.

Authors:  Carlos King Ho Wong; Kristy Tsz Kwan Lau; Eric Ho Man Tang; Chi Ho Lee; Carmen Yu Yan Lee; Yu Cho Woo; Ivan Chi Ho Au; Kathryn Choon Beng Tan; David Tak Wai Lui
Journal:  Cardiovasc Diabetol       Date:  2022-06-03       Impact factor: 8.949

2.  Effect of Metformin on T2D-Induced MAM Ca2+ Uncoupling and Contractile Dysfunction in an Early Mouse Model of Diabetic HFpEF.

Authors:  Maya Dia; Christelle Leon; Stephanie Chanon; Nadia Bendridi; Ludovic Gomez; Jennifer Rieusset; Helene Thibault; Melanie Paillard
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 3.  Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.

Authors:  Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Francesca Coviello; Anna Di Martino; Gaetana Albanese; Raffaele Marfella; Celestino Sardu; Ferdinando Carlo Sasso
Journal:  Biomolecules       Date:  2021-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.